{"id":"NCT05523297","sponsor":"Octapharma","briefTitle":"Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery","officialTitle":"Prospective, Multicenter, Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Bleeding Adult Cardiac Surgical Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-11-30","primaryCompletion":"2024-06-27","completion":"2024-06-27","firstPosted":"2022-08-31","resultsPosted":"2025-08-15","lastUpdate":"2025-08-15"},"enrollment":420,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Bleeding Cardiac Surgery Patients"],"interventions":[{"type":"DRUG","name":"Octaplex","otherNames":[]},{"type":"DRUG","name":"Frozen Plasma Product, Human","otherNames":[]}],"arms":[{"label":"Octaplex","type":"EXPERIMENTAL"},{"label":"Frozen plasma","type":"ACTIVE_COMPARATOR"}],"summary":"This is a multicenter, active-control randomized, prospective, Phase 3 study in adult cardiac surgery patients. 420 patients were randomized at 12 hospitals.","primaryOutcome":{"measure":"Number of Patients Requiring Additional Hemostatic Intervention","timeFrame":"60 minutes to 24 hours after first dose of IMP","effectByArm":[{"arm":"Octaplex","deltaMin":166,"sd":null},{"arm":"Frozen Plasma","deltaMin":125,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":13,"countries":["United States","Canada"]},"refs":{"pmids":["40156829","39174056"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":77,"n":213},"commonTop":["Atrial fibrillation","Anemia","Hypervolemia","Pleural effusion","Edema peripheral"]}}